Skip Ribbon Commands
Skip to main content
Navigate Up
Sign In

 Latest News

The study presents a cost-effective treatment option for patients with chronic genotype 1 HCV infection
​A systematic literature review was conducted to provide an overview of published literature in the last 10-years.
The model allows patients to move through a treatment sequence with treatment response measured via ACR criteria
ISPOR and Value in Health, journal for research that advance the field of pharmacogenomics and outcomes research, endorse Pharmerit’s academic research on reimbursement in Scotland.
Type 2 diabetes mellitus is estimated to account for 7–12% of the UK National Health Service expenditure. Economic analysis is critical to ensuring that limited resources are used effectively.
Analysis demonstrates the sublingual native 5-grass tablet to be cost-effective relative to a mix of subcutaneous allergoid compounds
Pharmerit Europe has a new management team of Bram Verheggen, Maarten Treur, and Stephanie Stephens. Together they are responsible for all aspects of Pharmerit Europe, but each has their own key focus.
Pharmerit conducted an analysis to estimate the incremental cost-effectiveness of hexaminolevulinate for patients diagnosed with non-muscle invasive bladder cancer (NMIBC) in Italy
Despite its rarity, anal cancer places a significant economic burden on the public purse and moreover resource pressures on the national health service.
We have enjoyed meeting you at the 17th European ISPOR conference in Amsterdam, November 2014. Hand-outs of the poster sessions are available on our ISPOR Amsterdam event page.
Contact Feel free to contact us if you have any questions